Research Article

Related GMR Articles

06/29/2015
Advanced ovarian cancer; ERCC1; Irinotecan and cisplatin; UGT1A1

The aim of this study was to define the genotypes of UGT1A1 and ERCC1 and to examine their relationship with the efficacy and toxicity of a combination therapy of irinotecan and cisplatin in patients with advanced ovarian cancer. The allelic frequencies of the UGT1A1 and ERCC1 variants in a group of 89 patients with advanced ovarian cancer were determined. ... more

Q. Xu; Y.Y. Ding; L.X. Song; J.F. Xu
03/31/2015
ERCC1; ERCC2; Glioma; Polymorphism

Several studies have examined the association between excision repair cross-complementation group 1 (ERCC1) C8092A and ERCC2 Lys751Gln polymorphisms and glioma risk, but the results have been inconclusive. We conducted a meta-analysis of 12 studies to determine the association between ERCC1 rs3212986 and ERCC2 rs13181 genes and glioma susceptibility. We searched for relevant studies in ... more

C.X. Zhou; J.H. Zhao
09/21/2015
ATP-binding cassette B1 gene; Clinical outcome; Traumatic brain injury

The critical role of ATP-binding cassette B1 (ABCB1) in the function of the blood-brain barrier led us to conducted this prospective study in order to investigate the clinical outcome of patients suffering from severe traumatic brain injury. A total of 182 patients with traumatic brain injury were included in our study. Genotyping of ABCB1 C3435T and G2677T/A was conducted using ... more

Z.L. Wang; D.S. Xu; Y.X. Wang; H. Qin; D. Geng
12/07/2015
Clinical outcome; Non-small cell lung cancer; Polymorphism; VEGF

This report details a study conducted to assess the role of VEGF gene polymorphisms in the prognosis of advanced non-small cell lung carcinoma (NSCLC). Samples obtained from 210 advanced NSCLC patients admitted at the Huaihe Hospital of Henan University between January 2010 and December 2011 were recruited for this study. The VEGF -2578C/A (rs699947), +936C/T (rs3025039), and -634G/C ( ... more

N. Chen; C.N. Ma; M. Zhao; Y.J. Zhang
06/03/2016
Clinical outcome; GSTP1 Ile105Val; Non-small cell lung carcinoma; XRCC1 Arg194Trp; XRCC1 Arg399Gln

Glutathione S-transferase P1 (GSTP1) and X-ray repair cross-complementing group 1 (XRCC1) genetic variations may in­fluence the efficacy of chemotherapy in various cancers. We investi­gated the possible roles of GSTP1 Ile105Val and XRCC1 Arg194Trp, and Arg399Gln gene polymorphisms in the prognosis of advanced non-small cell lung carcinoma ( ... more

L. Bu; L.B. Zhang; X. Mao; P. Wang; L. Bu; L.B. Zhang; X. Mao; P. Wang
06/24/2016
EC-9706 cells; EGFR; ERCC1; Esophageal cancer; p53; SNX-2112

SNX-2112 is a potential molecular targeted therapeutic drug against esophageal cancer (EC). However, its exact mechanism of action remains to be explained. The aim of this study was to investigate the effect of SNX-2112 on excision repair cross- complementing 1 (ERCC1), epidermal growth factor receptor (EGFR), and p53, to elucidate the mechanism of action of SNX-2112 on EC. Fresh tumor ... more

C.Y. Li; Y.J. Ren; Y.D. Li; C.Y. Li; Y.J. Ren; Y.D. Li
05/23/2016
Bladder cancer; Chemotherapy; ERCC1; Polymorphism

This study aims to investigate the association between ERCC1 codon C118T polymorphism and the response rate of platinum-based chemotherapy in patients with late-stage bladder cancer. A total of 41 eligible patients histologically confirmed as having stage IV muscle-invasive transitional cell carcinoma of the bladder were treated with platinum-based chemotherapy for 2-6 cycles. ... more

Z.C. Xu; H.Z. Cai; X. Li; W.Z. Xu; T. Xu; B. Yu; Q. Zou; L. Xu; Z.C. Xu; H.Z. Cai; X. Li; W.Z. Xu; T. Xu; B. Yu; Q. Zou; L. Xu
10/19/2015
ERCC2; Glioma; Meta-analysis; rs13181

Several studies have focused on the association between the ERCC2 rs13181 polymorphism and glioma risk, but the results were inconclusive. We aimed to conduct a meta-analysis to investigate the role of ERCC2 rs13181 on the risk of glioma. We searched and collated the relevant studies in both Chinese and English through the PubMed, Web of Science, Cochrane Library, and ... more

T.L. Jia; H.J. Wu; H.B. Wang; W.B. Ma; B. Xing
03/31/2016
ERCC2; ERCC3; Osteosarcoma; Polymorphism

We conducted a case-control study to investigate the role of common SNPs in ERCC2 (rs13181 and rs1799793) and ERCC3 (rs4150441 and rs4150506) in the development of osteosarcoma. A 1:2 matched case-control study was conducted. Between January 2012 and December 2013, 141 patients with pathologically diagnosed osteosarcoma and 282 controls were recruited in our study. Genotyping of ERCC2 ... more

X. Ma; Y. Zhang; T.S. Sun; J.H. Yao; X. Ma; Y. Zhang; T.S. Sun; J.H. Yao; X. Ma; Y. Zhang; T.S. Sun; J.H. Yao
03/01/2012
Bone neoplasms; Osteochondroma; Osteosarcoma

Osteochondroma is a cartilage capped benign tumor developing mainly at the juxta-epiphyseal region of long bones. The rate of malignant transformation, mainly into chondrosarcoma, is estimated to be less than 1-3%. Transformation into osteosarcoma is very rare and has been reported only thirteen times. There is little information on treatment and outcome. We report the case of a secondary ... more

E.E. Engel; M.H. Nogueira-Barbosa; M.S. Brassesco; G.E.B. Silva; E.T. Valera; F.M. Peria; T.C. Motta; L.G. Tone

Pages